Company news
Sab Biotherapeutics, Inc. (NASDAQ:SABS) news
Sab Biotherapeutics, Inc. news releases on 6ix. Latest, Feb 23, 2024: SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
Press releases — page 2
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 22, 2024
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 7, 2024
SAB Biotherapeutics Announces Executive Leadership Change
February 1, 2024
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 22, 2024
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 1, 2024
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
November 28, 2023
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
November 19, 2023
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
November 13, 2023
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
November 13, 2023
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
November 8, 2023
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
October 23, 2023
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
October 18, 2023
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
October 4, 2023
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
October 1, 2023
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
August 20, 2023
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
June 20, 2023
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
May 29, 2023
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
May 18, 2023
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
May 15, 2023
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
May 11, 2023
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
May 8, 2023
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
May 3, 2023
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
April 25, 2023
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
April 17, 2023
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
April 12, 2023
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
April 3, 2023
SAB Biotherapeutics Provides Company Update for Full Year 2022
March 30, 2023
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
January 17, 2023
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
January 9, 2023
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
January 4, 2023
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
December 6, 2022
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
November 20, 2022
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
November 14, 2022
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
October 26, 2022
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
September 27, 2022
SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
September 22, 2022
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
August 9, 2022
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
August 8, 2022
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
July 10, 2022
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
June 5, 2022
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
May 11, 2022
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
April 4, 2022
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
March 28, 2022
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
March 1, 2022
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
February 28, 2022
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
February 24, 2022
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
January 23, 2022
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 15, 2021
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
November 30, 2021
SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
November 21, 2021